Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...

Your doctor has recommended expanding your treatment plan for rheumatoid arthritis (RA) to include an interleukin 6 (IL-6) inhibitor — a biologic that’s often prescribed when conventional ...

The US Food and Drug Administration (FDA) has approved the biosimilar tocilizumab-aazg (Tyenne), Fresenius Kabi, the drug's manufacturer, announced today. This is the second tocilizumab biosimilar ...

Subcutaneous tocilizumab, alone or with methotrexate, showed superior efficacy over methotrexate monotherapy in treating rheumatoid arthritis in Chinese patients. The trial demonstrated higher ACR20 ...

Subcutaneous tocilizumab, either as monotherapy or in combination with methotrexate, demonstrated greater efficacy than methotrexate alone and was well tolerated in patients with active rheumatoid ...